Raymond James Financial Services Advisors Inc. Sells 2,868 Shares of DaVita Inc. (NYSE:DVA)

Raymond James Financial Services Advisors Inc. trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 15.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 15,491 shares of the company’s stock after selling 2,868 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in DaVita were worth $1,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of DVA. Norges Bank bought a new position in shares of DaVita during the 4th quarter valued at $116,373,000. Deutsche Bank AG increased its stake in DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock worth $103,518,000 after buying an additional 885,195 shares in the last quarter. Amundi increased its stake in DaVita by 226.3% in the 4th quarter. Amundi now owns 659,372 shares of the company’s stock worth $52,592,000 after buying an additional 457,285 shares in the last quarter. Morgan Stanley increased its stake in DaVita by 37.9% in the 4th quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock worth $92,042,000 after buying an additional 339,051 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in DaVita by 912.4% in the 4th quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company’s stock worth $25,249,000 after buying an additional 304,739 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Trading Down 0.5 %

Shares of NYSE DVA opened at $131.40 on Friday. The business’s 50 day moving average is $128.57 and its two-hundred day moving average is $107.66. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $141.54. The stock has a market capitalization of $11.52 billion, a P/E ratio of 17.76, a PEG ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The company had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.01 billion. During the same period in the previous year, the firm posted $1.11 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, research analysts expect that DaVita Inc. will post 9.23 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DVA. UBS Group increased their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a research report on Monday. Truist Financial raised their price objective on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. Finally, Barclays began coverage on DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective for the company. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $118.50.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the sale, the insider now directly owns 81,297 shares of the company’s stock, valued at $9,814,986.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the transaction, the insider now owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The disclosure for this sale can be found here. Insiders have sold 134,540 shares of company stock valued at $16,551,071 over the last ninety days. 1.40% of the stock is owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.